Literature DB >> 10855547

Gut-liver axis.

S Zeuzem1.   

Abstract

The gut and the liver are the key organs in nutrient absorption and metabolism. Bile acids, drugs, and toxins undergo extensive enterohepatic circulation. Bile acids play a major role in several hepatic and intestinal diseases. Endotoxins deriving from intestinal Gram-negative bacteria are important in the pathogenesis of liver and systemic diseases. Chronic liver diseases can influence gastrointestinal motility, which together with other factors may contribute to bacterial overgrowth and in patients with ascites to an increased risk of spontaneous bacterial peritonitis. Patients with end-stage liver disease frequently develop portal hypertension leading to varices, gastric vascular ectasia, and portal hypertensive gastroenteropathy. Several liver and biliary abnormalities are observed in patients with inflammatory bowel disease (primary sclerosing cholangitis, autoimmune hepatitis, cholelithiasis). The primary defect in hemochromatosis is located in the intestine, causing an inappropriate increase in iron absorption, and the liver is the site of earliest and heaviest iron deposition. Elevated transaminases are observed in many patients with celiac disease, and steatohepatitis frequently develops in patients with jejunoileal bypass and short bowel syndrome. Furthermore, the liver is the primary organ for metastasis of intestinal cancer. Many viral, bacterial, fungal, and parasitic diseases affect the intestine as well as the liver and the biliary tract.

Entities:  

Mesh:

Year:  2000        PMID: 10855547     DOI: 10.1007/s003840050236

Source DB:  PubMed          Journal:  Int J Colorectal Dis        ISSN: 0179-1958            Impact factor:   2.571


  37 in total

Review 1.  Enterohepatic circulation: physiological, pharmacokinetic and clinical implications.

Authors:  Michael S Roberts; Beatrice M Magnusson; Frank J Burczynski; Michael Weiss
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

2.  Intestinal microbiota was assessed in cirrhotic patients with hepatitis B virus infection. Intestinal microbiota of HBV cirrhotic patients.

Authors:  Haifeng Lu; Zhongwen Wu; Wei Xu; Jiezuan Yang; Yunbo Chen; Lanjuan Li
Journal:  Microb Ecol       Date:  2011-02-01       Impact factor: 4.552

3.  Effects of melatonin or acetylsalicylic acid on gastric oxidative stress after bile duct ligation in rats.

Authors:  Alaaddin Polat; Memet Hanifi Emre
Journal:  J Gastroenterol       Date:  2006-05       Impact factor: 7.527

4.  Clinical features of chronic C virus hepatitis in patients with celiac disease.

Authors:  M Silano; U Volta; O Vincentini; M De Vincenzi
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2009-06-16       Impact factor: 3.267

Review 5.  Gut microbiota: its role in hepatic encephalopathy.

Authors:  Rahul Rai; Vivek A Saraswat; Radha K Dhiman
Journal:  J Clin Exp Hepatol       Date:  2014-12-16

Review 6.  Gut-liver axis in liver cirrhosis: How to manage leaky gut and endotoxemia.

Authors:  Hiroshi Fukui
Journal:  World J Hepatol       Date:  2015-03-27

Review 7.  Microbiota and nonalcoholic steatohepatitis.

Authors:  Kento Imajo; Masato Yoneda; Yuji Ogawa; Koichiro Wada; Atsushi Nakajima
Journal:  Semin Immunopathol       Date:  2013-12-14       Impact factor: 9.623

Review 8.  Targeting gut microbiota in hepatocellular carcinoma: probiotics as a novel therapy.

Authors:  Murphy L Y Wan; Hani El-Nezami
Journal:  Hepatobiliary Surg Nutr       Date:  2018-02       Impact factor: 7.293

Review 9.  Prebiotics, probiotics, synbiotics in surgery--are they only trendy, truly effective or even dangerous?

Authors:  Nada Rayes; Daniel Seehofer; Peter Neuhaus
Journal:  Langenbecks Arch Surg       Date:  2008-12-16       Impact factor: 3.445

10.  Platelet-dependent accumulation of leukocytes in sinusoids mediates hepatocellular damage in bile duct ligation-induced cholestasis.

Authors:  M W Laschke; S Dold; M D Menger; B Jeppsson; H Thorlacius
Journal:  Br J Pharmacol       Date:  2007-11-19       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.